VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Clinical trial NCT06264180 · RECRUITING
Trial details
- NCT number
- NCT06264180
- Sponsor
- Replimune, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-11
- Primary completion
- 2030-09-30
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.